G211000

DMT-2′O-TBDMS-rG(ib) Phosphoramidite

• Synonim(y): N-(2-methyl-1-oxopropyl)-5′-O-[bis(4-methoxyphenyl)phenylmethyl]-2′-O-[(1,1-dimethylethyl)dimethylsilyl]-guanosine, 3′-[2-cyanoethyl N,N-bis(1-methylethyl)phosphoramidite]
• Wzór empiryczny (zapis Hilla): C₅₀H₆₈N₇O₉PSi
• Numer CAS: 147201-04-5
• Masa cząsteczkowa: 970.18
• NACRES: NA.51
• PubChem Substance ID: 329799851
• UNSPSC Code: 12352200
• MDL number: MFCD00080299
• Assay: ≥99% (³¹P-NMR), ≥99.0% (reversed phase HPLC)
• Biological source: non-animal source (no BSE/TSE risk)
• Form: powder
• Storage temp.: −20°C

Właściwości

• biological source: non-animal source (no BSE/TSE risk)
• Quality Segment: 300, 200
• product line: Proligo Reagents
• assay: ≥99% (³¹P-NMR), ≥99.0% (reversed phase HPLC)
• form: powder
• technique(s): oligo synthesis: suitable
• impurities: ≤0.3 wt. % water content (Karl Fischer), ≤0.5% P(III) Impurities 100-169ppm (³¹P-NMR), ≤0.5% single Impurity (reversed phase HPLC), ≤3 wt. % residual Solvent content
• color: white to off-white
• λ: conforms (UV/VIS Identity)
• suitability: conforms to structure for H-NMR, conforms to structure for LC-MS
• nucleoside profile: base: guanosine; base protecting group: isobutyryl; 2' protecting group: TBDMS; 5' protecting group: DMT; deprotection: standard
• storage temp.: −20°C
• SMILES string: COc1ccc(cc1)C(OC[C@H]2O[C@H]([C@H](O[Si](C)(C)C(C)(C)C)[C@@H]2OP(OCCC#N)N(C(C)C)C(C)C)n3cnc4C(=O)NC(NC(=O)C(C)C)=Nc34)(c5ccccc5)c6ccc(OC)cc6
• InChI: 1S/C50H68N7O9PSi/c1-32(2)45(58)54-48-53-44-41(46(59)55-48)52-31-56(44)47-43(66-68(12,13)49(7,8)9)42(65-67(63-29-17-28-51)57(33(3)4)34(5)6)40(64-47)30-62-50(35-18-15-14-16-19-35,36-20-24-38(60-10)25-21-36)37-22-26-39(61-11)27-23-37/h14-16,18-27,31-34,40,42-43,47H,17,29-30H2,1-13H3,(H2,53,54,55,58,59)/t40-,42-,43-,47-,67?/m1/s1
• InChI key: PGJKESPHANLWME-FTZVBZPOSA-N

Opis

General description

DMT-2′O-TBDMS-rG(ib) Phosphoramidite belongs to the group of 2′O-TBDMS RNA Phosphoramidites.

Application

RNA interference (RNAi) has become a popular tool for the sequence-specific inhibition of gene expression and can be used in target validation and other drug development techniques. The most convenient method to provide sequence-specific RNA oligonucleotides is a chemical synthesis on a solid support with RNA phosphoramidites and RNA CPG, analogous to DNA synthesis.

Features and Benefits

• Industry standard 2′O-TBDMS protective group
• Consistent lot-to-lot purity and performance
• Compatible with deprotection methods based on methylamine or AMA
• Standard RNA phosphoramidites provide excellent coupling results when used with ETT or BTT as an activator; best results are obtained with Activator 42
• Capping with standard acetic anhydride capping reagent rather than with Fast Deprotection Cap A
• Manufactured under a certified ISO 9001 quality system

Other Notes

The unique properties of RNA have stimulated the development of a variety of applications in diagnostics and therapeutics, as well as in basic molecular biology research where RNA can be used as:

• Catalytic agents (ribozymes)
• Affinity ligands (aptamers)
• Agents to induce gene silencing (RNA interference)

Ta strona może zawierać tekst przetłumaczony maszynowo.

Informacja o środkach bezpieczeństwa

• Klasa składowania: 11 - Combustible Solids
• wgk: WGK 2
• flash_point_f: Not applicable
• flash_point_c: Not applicable